India is the third largest pharmaceuticals industry in the world by volume and unsurprisingly, is referred to as the ‘pharmacy of the world’ where Indian companies account for a 20% share in the global supply of generic medicines, and for 62% of global supply of vaccines. The Indian pharmaceutical industry is expected to grow to £93bn by 2030. This amounts to a strong business opportunity for UK suppliers and exporters where the Indian bio-pharma industry is looking to move up the value chain by investing in new drug discovery and delivery, vaccines as well as nutraceuticals for preventive care.
The Indian biopharmaceutical market provides a plethora of opportunities for UK suppliers and exporters, whether you are a large multinational player or a UK SME. India’s large, youth demographic and a rising, more affluent middle class has increased demand for healthcare products and services. For example, nutraceutical products as a sector is poised to grow by 17% to £13bn by 2025. Additionally, there is increased demand for innovative drug discovery and delivery solutions, including digital therapeutics, and process manufacturing technologies.
Companies can leverage India as a hub to export to markets across the world due to the global reach of Indian pharmaceutical companies.
Lastly, India shares a common language and culture with the UK, as well as business, legal practices and the rule of law. This makes it easier for UK companies to do business there. This combined with the Government of India’s efforts to attract companies to India, in order to build resilient supply chains in API and critical drugs manufacturing further supports UK businesses, making India-UK collaboration in these areas vital.
Why attend:
Chance to interact with key stakeholders and influencers from the Indian healthcare and life sciences industry.
Hear from high profile speakers from organisations on key issues/ opportunities from policy to market access stories and industry trends in India.
Be part of a strong delegation to showcase the UK’s unique strengths in the Biopharma and Nutraceutical spectrum.
2 days of focussed 1:1 virtual meetings with potential buyers/ partners.
Dedicated support from the DIT network.
Mission Details:
Date: 30th November and 1st December 2021
Mission leads:
Aphrodite Spanou - Deputy Director, Healthcare, Life Sciences and Chemicals Directorate/ DIT
Guest of Honour - Alan Gemmell OBE (Her Majesty’s Trade Commissioner for South Asia)
Format of the (virtual) mission:
Day 1: 08:30hrs to 13:30hrs UK Time / 13:00hrs to 18:00hrs IST
Session 1: Indian Industry requirements and regulatory landscape (panel discussion)
Session 2: Pitching session for UK companies
Session 3: Networking session
Day 2: 09:00hrs – 13:30 hrs UK Time / 13:30hrs to 18:00hrs IST
All day: Networking sessions
Companies need to apply by 1 October, and the virtual mission kicks off on 30 November. The cost is £220, payable via OMIS. More details on the India market can be accessed via this link https://eu.eventscloud.com/website/5644/missions/